CLDX shares -5.3% premarket after saying its experimental drug barzolvolimab failed in a Phase 2 study in the skin condition prurigo nodular
CLDX shares -5.3% premarket after saying its experimental drug barzolvolimab failed in a Phase 2 study in the skin condition prurigo nodularis; is continuing to test the drug in a number of other indications, with data expected in September or October from Phase 3 trials in chronic spontaneous urticaria.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.